Is a
Clinical Study attributes
NCT Number
Trial Recruitment Size
500
Trial Sponsor
Clinical Trial Start Date
December 15, 2022
0Primary Completion Date
December 31, 2024
0Study Completion Date
December 31, 2024
0Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Treatment0
Intervention Type
Drug0
Intervention Name
Placebo0
INT-7870
Interventional Trial Phase
Phase 20
Participating Facility
Official Name
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis0
Last Updated
December 27, 2023
0Allocation Type
Randomized0
Intervention Model
Single Group Assignment0
Masking Type
Triple0
Masked Party
Participant0
Care Provider0
Investigator0
Study summary
The purpose of this trial is to assess dose related safety, efficacy, and pharmacokinetics (PK) of INT-787 in participants with severe alcohol-associated hepatitis (sAH).
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
